

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No.	50026/052001
				Serial No.	10/532,172
				Applicant	OKANO et al
				371(c) Date	August 29, 2005
				Group	1653
				IDS Filed	March 7, 2006
(37 C.F.R. § 1.98(b))					

U.S. PATENT DOCUMENTS							
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant		Class	Subclass	Filing Date (If Appropriate)
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION							
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)	
IP	WO 03/095663	November 20, 2003	WIPO				
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)							
IP	European Search Report for PCT/JP03/13476 (Mailed 6 February 2006)						

EXAMINER	/Ileana Popa/	DATE CONSIDERED	05/07/2006
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.			

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No.	50026/052001
		INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/532,172
				Applicant	Okano et al.
				Filing Date	April 21, 2005
				Group	Not Yet Assigned
		(37 C.F.R. § 1.98(b))		IDS Filed	OCTOBER 7, 2005

U.S. PATENT DOCUMENTS

Examiner's Initials	Document Number	Issue or Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
IP	2002/0098576	Jul. 25, 2002	Nagai et al.			
	2002/0100066 A1	Jul. 25, 2002	Nagai et al.			
	2002/0002143	Jan. 03, 2002	Kano et al.			
	2002/0169306 A1	Nov. 14, 2002	Kitazato et al.			
	2003/0166252 A1	Sep. 4, 2003	Kitazato et al.			
	2003/0170210	Sep. 11, 2003	Masaki et al.			
	2003/0170266 A1	Sep. 11, 2003	Kitazato et al.			
	2003/0170897	Sep. 11, 2003	Imai et al.			
	2004/0121308	Jun. 24, 2004	Nagai et al.			
	2004/0005296	Jan. 08, 2004	Yonemitsu et al.			
	2003/0203489	Oct. 30, 2003	Yonemitsu et al.			
	2004/0053877	Mar. 18, 2004	Fukumura et al.			
	2004/0101965	May 27, 2004	Griesenbach et al.			
	5,962,274	Oct. 5, 1999	Parks			
	6,040,174	Mar. 21, 2000	Imler et al.			
	6,645,760	Nov. 11, 2003	Nagai et al.			
	6,723,532	Apr. 20, 2004	Nagai et al.			
	6,746,860	Jun. 8, 2004	Tokusumi et al.			
IP	6,828,138	Dec. 7, 2004	Nagai et al.			

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
IP	AU 7335196 A	May 22, 1997	Australia			
IP	CA 2236113 A1	May 9, 1997	Canada			
IP	CN 1207123 A, B	Feb. 3, 1999	China			

EXAMINER /Ileana Popa/ DATE CONSIDERED 05/07/2006

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

<p>SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)</p> <p>(37 C.F.R. § 1.98(b))</p>				Attorney Docket No. 50026/052001	Serial No. 10/532,172	Applicant Okano et al.	Filing Date April 21, 2005	Group Not Yet Assigned	IDS Filed OCTOBER 7, 2005
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS									
Examiner's Initials	Document Number	Publication Date	Country or Patent Office		Class	Subclass	Translation (Yes/No)		
IP	CN 1357044 A	Jul. 3, 2002	China				No		
	EP 0 863 202 A1	Sep. 9, 1998	EPO						
	EP 0 864 645 A1	Sep. 16, 1998	EPO						
	EP 1 106 692 A1	Jun. 13, 2001	EPO						
	EP 1 179 594 A1	Feb. 13, 2002	EPO						
	EP 1 325 960 A2	Jul. 9, 2003	EPO						
	HK 1018287 A1	Nov. 21, 2003	Hong Kong						
	JP 7-509616 A1	Oct. 26, 1995	Japan				Claims only		
	JP 10-506542A1	Jun. 30, 1998	Japan				Yes		
	WO 97/16171A1	May 9, 1997	WIPO				Abstract only		
	WO 97/16538A1	May 9, 1997	WIPO				Yes		
	WO 00/27430A3	May 18, 2000	WIPO				Abstract only		
	WO 00/70055	Nov. 23, 2000	WIPO				Yes		
	WO 00/70070A1	Nov. 23, 2000	WIPO				Yes		
	WO 01/32898A3	May 10, 2001	WIPO						
	WO 03/092738A1	Nov. 13, 2003	WIPO				Yes		
	WO 03/093476A1	Nov. 13, 2003	WIPO				Yes		
	WO 03/102183A1	Dec. 11, 2003	WIPO				Yes		
	WO 2004/038029A1	May 6, 2004	WIPO				Yes		
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)									
	Ali and Nayak, "Assembly of Sendai Virus: M Protein Interacts with F and HN Proteins and with the Cytoplasmic Tail and Transmembrane Domain of F Protein," <i>Virology</i> 276(2):289-303 (2000).								
	Altenschmidt et al., "Specific Cytotoxic T Lymphocytes In Gene Therapy," <i>J. Mol. Med.</i> 75(4):259-266 (1997).								
IP	Auten et al., "Effect of Scaffold Attachment Region on Transgene Expression in Retrovirus Vector-Transduced Primary T Cells and Macrophages," <i>Hum. Gene Ther.</i> 10(8):1389-1399 (1999).								
EXAMINER		/Ileana Popa/		DATE CONSIDERED		05/07/2006			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.									

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No.	50026/052001
		INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/532,172
				Applicant	Okano et al.
				Filing Date	April 21, 2005
				Group	Not Yet Assigned
				IDS Filed	OCTOBER 7, 2005
(37 C.F.R. § 1.98(b))					
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)					
IP	Ayuk et al., "Establishment of an Optimised Gene Transfer Protocol for Human Primary T Lymphocytes According to Clinical Requirements," <i>Gene Ther.</i> 6(10):1788-1792 (1999).				
	Bagai et al., "Hemagglutinin-Neuraminidase Enhances F Protein-Mediated Membrane Fusion of Reconstituted Sendai Virus Envelopes with Cells," <i>J. Virol.</i> 67(6):3312-3318 (1993).				
	Barclay and Palese, "Influenza B Viruses with Site-Specific Mutations Introduced into the HA Gene," <i>J. Virol.</i> 69(2):1275-1279 (1995).				
	Bitzer et al., "Sendai Virus Efficiently Infects Cells via the Asialoglycoprotein Receptor and Requires the Presence of Cleaved F ₀ Precursor Proteins for this Alternative Route of Cell Entry," <i>J. Virol.</i> 71(7):5481-5486 (1997).				
	Blaese et al., "T Lymphocyte-Directed Gene Therapy for ADA-SCID: Initial Trial Results After 4 Years," <i>Science</i> 270(5235):475-480 (1995).				
	Brenner, "Gene Transfer to Hematopoietic Cells," <i>New Eng. J. Med.</i> 335(5):337-339 (1996).				
	Brown and Rose, "Sorting of GPI-Anchored Proteins to Glycolipid-Enriched Membrane Subdomains during Transport to the Apical Cell Surface," <i>Cell</i> 68(3):533-544 (1992).				
	Buchschafer and Wong-Staal, "Development of Lentiviral Vectors for Gene Therapy for Human Diseases," <i>Blood</i> 95(8):2499-2504 (2000).				
	Bunnell et al., "Efficient In Vivo Marking of Primary CD4+ T Lymphocytes in Nonhuman Primates Using a Gibbon Ape Leukemia Virus-Derived Retroviral Vector," <i>Blood</i> 89(6):1987-1995 (1997).				
	Cathomen et al., "A Matrix-Less Measles Virus Is Infectious and Elicits Extensive Cell Fusion: Consequences for Propagation in the Brain," <i>EMBO J.</i> , 17(14):3899-3908 (1998).				
	Conzelmann, "Nonsegmented Negative-Strand RNA Viruses: Genetics and Manipulation of Viral Genomes," <i>Annu. Rev. Genet.</i> , 32:123-162 (1998).				
	Costello et al., "Gene Transfer into Stimulated and Unstimulated T Lymphocytes by HIV-1-Derived Lentiviral Vectors," <i>Gene Ther.</i> 7(7):596-604 (2000)..				
	Dardalhon et al., "Lentivirus-mediated Gene Transfer in Primary T Cells Is Enhanced by a Central DNA Flap," <i>Gene Ther.</i> 8(3):190-198 (2001)				
	Di Nicola et al., "Recombinant Adenoviral Vector-LipofectA MINE Complex for Gene Transduction into Human T Lymphocytes," <i>Hum. Gene Ther.</i> 10(11):1875-1884 (1999).				
	Douglas et al., "Targeted Gene Delivery by Tropism-Modified Adenoviral Vectors," <i>Nat. Biotechnol.</i> 14(11):1574-1578 (1996).				
	Friedman, "Expression of Human Adenosine Deaminase Using a Transmissible Murine Retrovirus Vector System," <i>Proc. Natl. Acad. Sci. USA</i> 82(3):703-707 (1985).				
	Garoff et al., "Virus Maturation by Budding," <i>Microbiol. Mol. Biol. Rev.</i> , 62(4):1171-1190 (1998).				
IP	Gitman et al., "Use of Virus-Attached Antibodies or Insulin Molecules to Mediate Fusion Between Sendai Virus Envelopes and Neuraminidase-Treated Cells," <i>Biochemistry</i> 24(11):2762-2768 (1985).				
EXAMINER	/Ileana Popa/		DATE CONSIDERED	05/07/2006	
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.					

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No.	50026/052001
		INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/532,172
				Applicant	Okano et al.
				Filing Date	April 21, 2005
				Group	Not Yet Assigned
				IDS Filed	OCTOBER 7, 2005
(37 C.F.R. § 1.98(b))					
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)					
IP	Gladow et al., "MLV-10A1 Retrovirus Pseudotype Efficiently Transduces Primary Human CD4 ⁺ T Lymphocytes," <i>J. Gene Med.</i> 2(6):409-415 (2000).				
	Hasan et al., "Creation of an Infectious Recombinant Sendai Virus Expressing the Firefly Luciferase Gene from the 3' Proximal First Locus," <i>J. Gen. Virol.</i> , 78(Pt 11):2813-2820 (1997).				
	Hege and Roberts, "T-Cell Gene Therapy," <i>Curr. Opin. Biotechnol.</i> 7(6):629-634 (1996).				
	Heggeness et al., "In Vitro Assembly of the Nonglycosylated Membrane Protein (M) of Sendai Virus," <i>Proc. Natl. Acad. Sci. USA</i> , 79(20):6232-6236 (1982).				
	Huntley et al., "Phosphorylation of Sendai Virus Phosphoprotein by Cellular Protein Kinase C ζ ," <i>J. Biol. Chem.</i> 272(26):16578-16584 (1997).				
	Ikeda et al. "Recombinant Sendai Virus-Mediated Gene Transfer into Adult Rat Retinal Tissue: Efficient Gene Transfer by Brief Exposure," <i>Exp. Eye Res.</i> 75(1):39-48 (2002).				
	Imbert et al., "Highly Efficient Retroviral Gene Transfer into Human Primary T Lymphocytes Derived from Peripheral Blood," <i>Cancer Gene Ther.</i> 1(4):259-265 (1994).				
	Inoue et al., "A New Sendai Virus Vector Deficient in the Matrix Gene Does Not Form Virus Particles and Shows Extensive Cell-to-Cell Spreading," <i>J. Virol.</i> 77(11):6419-6429 (2003).				
	Karron et al., "Respiratory Syncytial Virus (RSV) SH and G Proteins Are Not Essential for Viral Replication <i>In Vitro</i> : Clinical Evaluation and Molecular Characterization of a Cold-Passaged, Attenuated RSV Subgroup B Mutant," <i>Proc. Natl. Acad. Sci. USA</i> 94(25):13961-13966 (1997).				
	Kato et al., "Initiation of Sendai Virus Multiplication from Transfected cDNA or RNA with Negative or Positive Sense," <i>Genes Cells</i> , 1(6):569-579 (1996).				
	Kido et al., "The Human Mucus Protease Inhibitor and its Mutants Are Novel Defensive Compounds Against Infection with Influenza A and Sendai Viruses," <i>Biopolymers (Peptide Science)</i> 51(1):79-86 (1999).				
	Kondo et al., "Temperature-Sensitive Phenotype of a Mutant Sendai Virus Strain Is Caused by its Insufficient Accumulation of the M Protein," <i>J. Biol. Chem.</i> 268(29):21924-21930 (1993).				
	Kühlicke et al., "Highly Efficient Retroviral Gene Transfer Based on Centrifugation-Mediated Vector Preloading of Tissue Culture Vessels," <i>Mol. Ther.</i> 5(4):473-478 (2002).				
	Lamb and Kolakofsky, "Paramyxoviridae: The Viruses and Their Replication," <i>Fields Virology</i> , 3 rd ed., B.N. Fields et al., Lippincott-Raven Publishers, Philadelphia, Chapter 40, p. 1181 (1996).				
	Leyrer et al., "Sendai Virus-Like Particles Devoid of Haemagglutinin-Neuraminidase Protein Infect Cells Via the Human Asialoglycoprotein Receptor," <i>J. Gen. Virol.</i> 79(Pt. 4):683-687 (1998).				
	Li et al., "A Cytoplasmic RNA Vector Derived from Nontransmissible Sendai Virus with Efficient Gene Transfer and Expression," <i>J. Virol.</i> 74(14):6564-6569 (2000).				
IP	Lin et al., "The RNA Binding Region of the Paramyxovirus SV5 V and P Proteins," <i>Virology</i> 238(2):460-469 (1997).				
EXAMINER	/Ileana Popa/		DATE CONSIDERED	05/07/2006	
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.					

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No. 50026/052001	Serial No. 10/532,172
		INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant Okano et al.	Filing Date April 21, 2005
		(37 C.F.R. § 1.98(b))		Group Not Yet Assigned	IDS Filed OCTOBER 7, 2005
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)					
IP	Manié et al., "Measles Virus Structural Components Are Enriched into Lipid Raft Microdomains: A Potential Cellular Location for Virus Assembly," <i>J. Virol.</i> 74(1):305-311 (2000).				
	Markwell et al., "An Alternative Route of Infection for Viruses: Entry by Means of the Asialoglycoprotein Receptor of a Sendai Virus Mutant Lacking its Attachment Protein," <i>Proc. Natl. Acad. Sci. USA</i> 82(4):978-982 (1985).				
	Matsumura et al., "RNA Editing-Like Phenomenon in Paramyxovirus V Gene mRNA Observed in Insect Cells Infected With a Recombinant Baculovirus," <i>J. Gen. Virol.</i> 80(Pt. 1):117-123 (1999).				
	Mebatsion et al., "Matrix Protein of Rabies Virus Is Responsible for the Assembly and Budding of Bullet-Shaped Particles and Interacts with the Transmembrane Spike Glycoprotein G," <i>J. Virol.</i> 73(1):242-250 (1999).				
	Misaki et al., "Gene-Transferred Oligoclonal T Cells Predominantly Persist in Peripheral Blood From an Adenosine Deaminase-Deficient Patient During Gene Therapy," <i>Mol. Ther.</i> 3(1):24-27 (2001).				
	Miura et al., "HVJ (Sendai Virus)-Induced Envelope Fusion and Cell Fusion Are Blocked by Monoclonal Anti-HN Protein Antibody That Does Not Inhibit Hemagglutination Activity of HVJ," <i>Exp. Cell Res.</i> 141(2):409-420 (1982).				
	Morikawa et al., "Characterization of Temperature-Sensitive Mutants of Measles Virus," <i>Kitasato Arch. of Exp. Med.</i> 64(1):15-30 (1991).				
	Movassagh et al., "Retrovirus-Mediated Gene Transfer into T Cells: 95% Transduction Efficiency Without Further In Vitro Selection," <i>Hum. Gene Ther.</i> 11(8):1189-1200 (2000).				
	Nagai, "Paramyxovirus Replication and Pathogenesis. Reverse Genetics Transforms Understanding," <i>Rev. Med. Virol.</i> 9(2):83-99 (1999).				
	Okano et al., "Recombinant Sendai Virus Vectors for Activated T Lymphocytes," <i>Gene Ther.</i> 10(16):1381-1391 (2003).				
	Pollok et al., "High-Efficiency Gene Transfer into Normal and Adenosine Deaminase-Deficient T Lymphocytes is Mediated by Transduction on Recombinant Fibronectin Fragments," <i>J. Virol.</i> 72(6):4882-4892 (1998).				
	Ponimaskin et al., "Sendai Virosomes Revisited: Reconstitution with Exogenous Lipids Leads to Potent Vehicles for Gene Transfer," <i>Virology</i> 269(2):391-403 (2000).				
	Puls and Minchin, "Gene Transfer and Expression of a Non-Viral Polycation-Based Vector in CD4 ⁺ Cells," <i>Gene Ther.</i> 6(10):1774-1778 (1999).				
	Ramani et al., "Novel Gene Delivery to Liver Cells Using Engineered Virosomes," <i>FEBS Lett.</i> 404(2-3):164-168 (1997).				
	Rosenberg et al., "Gene Transfer Into Humans—Immunotherapy of Patients with Advanced Melanoma, Using Tumor-Infiltrating Lymphocytes Modified by Retroviral Gene Transduction," <i>N. Eng. J. Med.</i> 323(9):570-578 (1990).				
	Rudolf et al., "High-Efficiency Retroviral Vector Mediated Gene Transfer into Human Peripheral Blood CD4 ⁺ T Lymphocytes," <i>Gene Ther.</i> 3(8):695-705 (1996).				
IP	Sakai et al., "Accommodation of Foreign Genes into the Sendai Virus Genome: Sizes of Inserted Genes and Viral Replication," <i>FEBS Lett.</i> 456(2):221-226 (1999).				
EXAMINER	/Ileana Popa/		DATE CONSIDERED	05/07/2006	
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.					

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No. 50026/052001
		INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No. 10/532,172
				Applicant Okano et al.
				Filing Date April 21, 2005
				Group Not Yet Assigned
				IDS Filed OCTOBER 7, 2005
(37 C.F.R. § 1.98(b))				
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)				
IP	Sanderson et al., "Sendai Virus Assembly: M Protein Binds to Viral Glycoproteins in Transit through the Secretory Pathway," <i>J. Virol.</i> 67(2):651-663 (1993).			
	Sanderson et al., "Sendai Virus M Protein Binds Independently to Either the F or the HN Glycoprotein <i>In Vivo</i> ," <i>J. Virol.</i> 68(1):69-76 (1994).			
	Schwartz et al., "Synthetic DNA-Compacting Peptides Derived from Human Sequence Enhance Cationic Lipid-Mediated Gene Transfer <i>In Vitro</i> and <i>In Vivo</i> ," <i>Gene Ther.</i> 6(2):282-292, 1999.			
	Shiotani et al. "Skeletal Muscle Regeneration After Insulin-Like Growth Factor I Gene Transfer by Recombinant Sendai Virus Vector," <i>Gene Ther.</i> 8(14):1043-1050 (2001).			
	Simons and Ikonen, "Functional Rafts in Cell Membranes," <i>Nature</i> 387(6633):569-572 (1997).			
	Spielhofer et al., "Chimeric Measles Viruses with a Foreign Envelope," <i>J. Virol.</i> 72(3):2150-2159 (1998).			
	Stockschläder et al., "Expansion and Fibronectin-Enhanced Retroviral Transduction of Primary Human T Lymphocytes for Adoptive Immunotherapy," <i>J. Hematother Stem Cell Res.</i> 8(4):401-410 (1999).			
	Stricker and Roux, "The Major Glycoprotein of Sendai Virus Is Dispensable for Efficient Virus Particle Budding," <i>J. Gen. Virol.</i> 72(Pt. 7):1703-1707 (1991).			
	Thompson and Portner, "Localization of Functional Sites on the Hemagglutinin-Neuraminidase Glycoprotein of Sendai Virus by Sequence Analysis of Antigenic and Temperature-Sensitive Mutants," <i>Virology</i> 160(1):1-8 (1987).			
	Tomasi et al., "Conjugation of Specific Antibodies to Sendai Virus Particles," <i>FEBS Lett.</i> 143(2):252-256 (1982).			
	Tuffereau et al., "The Role of Haemagglutinin-Neuraminidase Glycoprotein Cell Surface Expression in the Survival of Sendai Virus-Infected BHK-21 Cells," <i>J. Gen. Virol.</i> 66(11):2313-2318 (1985).			
	Tuohy and Mathisen, "T Cell Design for Therapy in Autoimmune Demyelinating Disease," <i>J. Neuroimmunol.</i> 107(2): 226-232 (2000).			
	Uchida et al., "High Efficiency Gene Transfer into Murine T Cell Clones Using a Retroviral Vector," <i>J. Immunol.</i> 136(5):1876-1879 (1986).			
	Wickham et al., "Targeted Adenovirus-Mediated Gene Delivery to T Cells Via CD3," <i>J. Virol.</i> 71(10):7663-7669 (1997).			
	Yonemitsu et al., "Efficient Gene Transfer to Airway Epithelium Using Recombinant Sendai Virus," <i>Nat. Biotechnol.</i> 18(9):970-973 (2000).			
	Yoshida et al., "Membrane (M) Protein of HVJ (Sendai Virus): Its Role in Virus Assembly," <i>Virology</i> 71(1):143-161 (1976).			
	Yu et al., "Sendai Virus-Based Expression of HIV-1 gp120: Reinforcement by the V(-) Version," <i>Genes to Cells</i> 2:457-466 (1997).			
IP	Zhirnov, "Solubilization of Matrix Protein M1/M from Virions Occurs at Different pH for Orthomyxo- and Paramyxoviruses," <i>Virology</i> 176(1):274-279 (1990).			
EXAMINER	/Ileana Popa/	DATE CONSIDERED	05/07/2006	
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.				